Evolent Health (NYSE:EVH) Stock Price Target Raised at Oppenheimer

Evolent Health (NYSE:EVH) had its price target hoisted by Oppenheimer from $6.00 to $7.00 in a research report released on Friday,Benzinga reports. Oppenheimer currently has an outperform rating on the technology company’s stock.

A number of other brokerages have also recently issued reports on EVH. Truist Financial dropped their price objective on Evolent Health from $7.00 to $6.00 and set a “hold” rating on the stock in a research note on Wednesday, August 12th. JPMorgan Chase & Co. raised their target price on shares of Evolent Health from $5.00 to $6.00 and gave the company an “overweight” rating in a research note on Tuesday, August 18th. Weiss Ratings downgraded shares of Evolent Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 16th. Citigroup raised shares of Evolent Health from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $6.75 to $6.00 in a research report on Monday, August 10th. Finally, TD Cowen upped their price target on shares of Evolent Health from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Eleven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $6.11.

Evolent Health Stock Up 1.4%

Shares of EVH stock traded up $0.07 during trading on Friday, reaching $4.61. The company’s stock had a trading volume of 1,743,939 shares, compared to its average volume of 1,816,949. Evolent Health has a one year low of $2.10 and a one year high of $6.28. The business has a fifty day moving average price of $4.17 and a 200-day moving average price of $3.88. The company has a market cap of $520.64 million, a price-to-earnings ratio of -1.01 and a beta of 1.03. The company has a quick ratio of 1.24, a current ratio of 1.24 and a debt-to-equity ratio of 2.52.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, November 5th. The technology company reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 4.27%. The firm had revenue of $725.37 million for the quarter, compared to analyst estimates of $727.06 million. During the same period in the previous year, the business earned $0.05 EPS. The company’s revenue was up 51.3% compared to the same quarter last year. Analysts anticipate that Evolent Health will post -0.25 earnings per share for the current year.

Insider Activity

In other news, President Daniel Mccarthy sold 65,892 shares of Evolent Health stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $5.00, for a total transaction of $329,460.00. Following the completion of the transaction, the president directly owned 655,133 shares in the company, valued at approximately $3,275,665. The trade was a 9.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.48% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Evolent Health

A number of large investors have recently added to or reduced their stakes in the business. R Squared Ltd bought a new position in Evolent Health during the first quarter worth $26,000. Royal Bank of Canada raised its position in shares of Evolent Health by 51.6% in the first quarter. Royal Bank of Canada now owns 25,161 shares of the technology company’s stock valued at $57,000 after purchasing an additional 8,563 shares during the period. Wealthfront Advisers LLC lifted its stake in shares of Evolent Health by 40.8% during the 1st quarter. Wealthfront Advisers LLC now owns 28,083 shares of the technology company’s stock worth $64,000 after buying an additional 8,136 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of Evolent Health during the 2nd quarter worth about $78,000. Finally, Vise Technologies Inc. boosted its holdings in shares of Evolent Health by 76.5% during the 3rd quarter. Vise Technologies Inc. now owns 30,215 shares of the technology company’s stock worth $105,000 after buying an additional 13,096 shares during the period.

Evolent Health News Summary

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Oppenheimer raised its price target to $7 from $6 and maintained an “outperform” rating, implying substantial upside from the cited $4.61 share price. Oppenheimer recommendations
• Positive Sentiment: Needham & Company lifted its target to $6 from $5 and kept a “buy” rating, adding to the favorable analyst outlook. Needham recommendations
• Positive Sentiment: EVH forecast fiscal 2026 revenue of $2.6 billion to $2.7 billion, with the top of the range above analysts’ $2.6 billion consensus. Third-quarter results and outlook
• Neutral Sentiment: Third-quarter adjusted earnings were $0.06 per share, matching estimates and improving from $0.05 a year earlier. Revenue rose 51.3% year over year to $725.37 million, but was slightly below the $727.06 million consensus. Third-quarter results
• Negative Sentiment: The reported quarter included a negative net margin of 24.08% and negative return on equity, highlighting that profitability remains a concern despite revenue growth and per-share earnings. Third-quarter results

About Evolent Health

Evolent Health, Inc (NYSE: EVH) is a healthcare services and technology company that helps health plans and healthcare providers transition to value-based care. Its platform is designed to support the management of clinical programs, improve patient outcomes and coordinate care while helping customers manage healthcare costs.

The company provides specialty and total-cost-of-care solutions across areas such as cardiology, oncology, musculoskeletal care, radiology and other complex conditions.